Journey Medical Corporation (DERM)

USD 4.71

(-2.48%)

Market Cap (In USD)

98.39 Million

Revenue (In USD)

79.18 Million

Net Income (In USD)

-3.85 Million

Avg. Volume

56.21 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.85-8.1
PE
-
EPS
-
Beta Value
0.924
ISIN
US48115J1097
CUSIP
48115J109
CIK
1867066
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Claude Maraoui
Employee Count
-
Website
https://journeymedicalcorp.com
Ipo Date
2021-11-12
Details
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.